How Changes To 'Dear Doctor Letters' Will Impact Industry
The U.S. Food and Drug Administration's guidance on "Dear Health Care Provider" ("DHCP") letters, finalized earlier this year, provides further clarity on the agency's expectations for the content, format and use...To view the full article, register now.
Already a subscriber? Click here to view full article